Accessibility Menu
Opus Genetics logo

Opus Genetics(NASDAQ) OCUP

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-39%
5 Year-19%
1 Year+197%
1 Month-2%
N/A
Opus Genetics last closing stock price
MetricPriceDate
Last closeUSD 3.622026-08-31
Opus Genetics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.17%USD 4.032026-08-24
1 month-2.43%USD 3.712026-07-31
3 month-9.27%USD 3.992026-06-02
Year to date+80.1%USD 2.012025-12-31
1 year+196.72%USD 1.222025-08-29
3 year-7.65%USD 3.922023-09-01
5 year-19.38%USD 4.492021-09-01
Since inception-38.5%USD 6.002020-11-06

Opus Genetics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.13M

Net Income (TTM)

-$107.61M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 11, 2024

OCUP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Opus Genetics

Opus Genetics creates treatments for rare eye conditions. These therapies target the genetic causes of blindness. The company aims to restore vision for patients.

Tools for Better Sight

  • OPGx-LCA5: Gene therapy for a severe form of retinal dystrophy; currently in Phase 1/2/3 clinical trials.
  • OPGx-BEST1: Candidate for vitelliform macular dystrophy; aims to stop progressive vision loss in adults.
  • Ryzumvi: FDA-approved eye drop for reversing pupil dilation; commercialized through a global partnership.
  • OPGx-RDH12: Gene therapy for retinal dystrophy; expected to enter clinical trials in late 2026.

Strategic Moves and Partnerships

  • Entered a license and collaboration agreement with Viatris in November 2022 to develop and commercialize phentolamine ophthalmic solution.
  • Secured a senior secured note purchase agreement with Oberland Capital in April 2026 for up to $155 million in funding.
  • Received FDA acceptance into the Rare Disease Evidence Principles program for OPGx-LCA5 in May 2026.
  • Completed enrollment for the registrational Phase 3 clinical trial of OPGx-LCA5 in August 2026.

What Makes the Tech Unique?

Opus utilizes specialized viral vectors to deliver functional genes directly to the retina. The company maintains multiple FDA designations for its lead programs, including Regenerative Medicine Advanced Therapy status.

Recent Financial Results

  • Net loss was $73.6 million for the six months ended June 30, 2026.
  • Cash and cash equivalents totaled $88.8 million as of June 30, 2026.
  • License and collaborations revenue was $2.9 million for the six months ended June 30, 2026.
  • Total operating expenses reached $33.8 million for the six months ended June 30, 2026.
  • Accumulated deficit was $262.2 million as of June 30, 2026.

Bottom Line

Opus has transitioned from a small-molecule developer to a gene therapy specialist targeting rare blindness. The company maintains a dual-track strategy involving internal gene therapy development and commercial partnerships for its eye drop products.

AI Generated • Aug 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

George Magrath, III, MD

Website

opusgtx.com

Headquarters

Farmington Hills, MI 48335, US

OCUP Financials

Key Financial Metrics (TTM)

Gross Margin

99.87%

Operating Margin

-513.47%

Net Income Margin

-1091.82%

Return on Equity

1147.63%

Return on Capital

-251.49%

Return on Assets

-115.75%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$5.13M

Operating Income

-$50.61M

EBITDA

-$27.32M

Operating Cash Flow

-$40.67M

Capital Expenditure

$0.00

Free Cash Flow

-$40.67M

Cash & ST Invst.

$88.81M

Total Debt

$34.93M

Opus Genetics Performance Analysis

Opus Genetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 39,850,0006665.7%
20232023-12-31USD 19,049,000-52.2%
20242024-12-31USD 10,992,000-42.3%
20252025-12-31USD 14,196,00029.1%
Opus Genetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Q22026-06-30N/A
Opus Genetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.87N/A
20232023-12-31USD -0.46N/A
20242024-12-31USD -2.15365.6%
20252025-12-31USD -0.80-63.0%
Opus Genetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-108.3%
Q42025-12-3124.0%
Q12026-03-31-294.7%
Q22026-06-3081.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$755.00K

N/A

Gross Profit

$755.00K

N/A

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

14

N/A

Net Income

-$8.10M

-9.1%

EBITDA

-$7.57M

-2.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$88.81M

+173.9%

Total Debt

$34.93M

N/A

Accounts Receivable

$1.46M

-68.2%

Inventory

$0.00

N/A

Long Term Debt

$34.93M

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.16%

N/A

Return on Invested Capital

-59.29%

N/A

Free Cash Flow

-$11.95M

-16.4%

Operating Cash Flow

-$11.95M

-16.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GRCEGrace Therapeutics, Inc.
$2.13+0.47%
MRNSMarinus Pharmaceuticals, Inc.
$0.55+0.00%
ANGNAngion Biomedica Corp.
$1.00+0.00%
ALLKAllakos Inc.
$0.33+0.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About OCUP

What is the current price of Opus Genetics?

Opus Genetics is trading at N/A per share.

What is the 52-week range for Opus Genetics?

Over the past 52 weeks, Opus Genetics has traded between N/A and N/A.

How much debt does Opus Genetics have?

As of the most recent reporting period, Opus Genetics reported total debt of $36.20M.

How much cash does Opus Genetics have on hand?

Opus Genetics reported $88.81M in cash and cash equivalents in its most recent financial results.

What is Opus Genetics’s dividend yield?

Opus Genetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services